Phase I study for poor-prognosis lymphoma: Augmentation of the “BEAM” regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation — a preliminary report-Reference-Cited by-同舟云学术

Phase I study for poor-prognosis lymphoma: Augmentation of the “BEAM” regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation — a preliminary report

Published:2004-12 Issue: Volume:31 Page:59-61
ISSN:0093-7754
Container-title:Seminars in Oncology
language:en
Short-container-title:Seminars in Oncology

Author:

Phillips G.L.,Abboud C.N.,Bernstein S.H.,Friedberg J.W.,Ifthikharuddin J.J.,Lancet J.E.,Liesveld J.L.,Spreng E.,Johnson V.,Chapman M.,Vesole D.H.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference13 articles.

1. High-dose therapy in lymphomas;Mink;Onocologist,2001

2. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma;Philip;N Engl J Med,1987

3. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkins lymphoma;Bierman;J Clin Oncol,2003

4. Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma;Salar;Bone Marrow Transplant,2001

5. Role of massive chemotherapy and autologous bone-marrow transplantation in non-Hodgkin’s malignant lymphoma;Philip;Lancet,1984

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bendamustine‐based conditioning prior to autologous stem cell transplantation (ASCT): Results of a French multicenter study of 474 patients from LYmphoma Study Association (LYSA) centers;American Journal of Hematology;2018-03-14

2. A Phase I Trial: Dose Escalation of Melphalan in the “BEAM” Regimen Using Amifostine Cytoprotection;Biology of Blood and Marrow Transplantation;2011-07

3. Novel Preparative Regimens in Hematopoietic Stem Cell Transplantation;Current Pharmaceutical Design;2008-07-01

4. Commentary: The Pharmacological Antioxidant Amifostine—Implications of Recent Research for Integrative Cancer Care;Integrative Cancer Therapies;2005-12

5. Current Awareness in Hematological Oncology;Hematological Oncology;2005-09-26